ClinicalTrials.gg
CompletedNCT06632483Updated Oct 28, 2026

An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions

An observational study in Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure, sponsored by Bayer. Completed at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Bayer · Observational

How we know

Updated Oct 28, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
604
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Heart Failure by Bayer — 6 open to participants now, 7 under way, 2 of them phase 3. Heart Failure · Bayer.

Enrollment
9th of 14
604 · median 1,175
Started
2025
with 3 others
Observational
14 of 47
4 open now
Registered
41st of 47
by date

Among the 47 studies in Heart Failure by Bayer, this one is the 9th largest by enrollment of the 14 observational ones that give a count, is one of 4 that started in 2025, is one of 14 observational ones, and was the 41st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 47 studies in Heart Failure by Bayer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Heart Failure by Bayer, or all of them as a file.
02

Study summary

This is an observational study in which data already collected from people with chronic HFrEF (heart failure with reduced ejection fraction) who have experienced worsening heart failure are studied.

Chronic HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body as well as it should. Blood and fluid may collect in the lungs, blood vessels, and tissues causing shortness of breath or tiredness. Over time, heart failure can lead to other serious medical conditions that may result in hospital stays and even death.

The study drug, vericiguat, is already approved for doctors to prescribe to people with worsening of heart failure with chronic HFrEF in India.

Vericiguat increases the activity of an enzyme called soluble guanylate cyclase (sGC), which relaxes the blood vessels, allowing more blood to flow through. As a result, the heart is able to pump better.

The participants in this study are already receiving treatment with vericiguat as part of their regular care from their doctors. There is currently limited real-world data on the use of vericiguat. Furthermore, discussing whether vericiguat treatment should start early in people with heart failure can help doctors manage these people better.

The main purpose of this study is to collect information about how well vericiguat works and how safe it is in Indian people with chronic HFrEF who have experienced worsening heart failure. To do this, researchers will collect the following information:

  • participants' characteristics, including age, sex, height, weight, and medical history
  • additional medicines participants have taken with vericiguat
  • other treatment options participants have taken for the treatment of heart failure
  • levels of NT-pro BNP* in participants' blood at least one month before taking vericiguat (*NT-proBNP is made by heart muscles. People with heart diseases have increased levels of NT-proBNP in their blood. Measuring NT-proBNP levels in the blood can help doctors identify heart disease.)
  • number of participants from India, divided into four zones-North, South, East, and West
  • categorization of participants based on how heart failure limits physical activity and classification of heart failure by cause
  • change in heart function measured by how much blood the left side of the heart can pump out
  • number of hospitalizations and number of participants who died due to heart-related and non-heart-related events
  • number of participants who experienced low blood pressure or fainting after starting treatment with vericiguat
  • participants who discontinued treatment with vericiguat, due to low blood pressure or fainting

The data will come from the participants' hospital, medical and electronic healthcare records. Data collected will be from Indian people with chronic HFrEF who started taking vericiguat between September 2022 and August 2023.

Researchers will track participants' data and will follow them until Feb 2024. In this study, only available data from routine care are collected. No visits or tests are required as part of this study.

03

Conditions studied

  • Chronic Heart Failure With Reduced Ejection Fraction
  • Worsening Chronic Heart Failure

Browse trials for

Keywords

  • HFrEF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The primary source of data is hospital medical records. The electronic health records or physical records of patients with HFrEF who were managed with Vericiguat will be screened to obtain the relevant baseline and follow-up data. Such records will be collected from 15 participating sites in India.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of ≥18 years age.
  • Patients who are prescribed as per local label will be included in the study
  • At least one Vericiguat prescription during the time between 01 Sep 2022 and 31 Aug 2023

Exclusion criteria

Exclusion Criteria:

  • Subjects who have participated in an interventional clinical study
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
604 participants (actual)
Patient registry
No

Groups and cohorts

  • Vericiguat

    New users who have been initiated on Vericiguat between 01 Sep 2022 and 31 Aug 2023 in 15 Sites in India

    Drug: Vericiguat (Verquvo, BAY1021189)

Interventions

06

What researchers measure

Primary outcomes

  1. Descriptive measurement of baseline clinical characteristics of patients initiated on Vericiguat

    Clinical characteristics include demographics, concomitant medication, medical history and surgical history, history of hospitalization, N-Terminal Pro Brain Natriuretic Peptide (NT-Pro BNP) levels

    Time frame: At baseline

  2. Descriptive measurement of baseline treatment patterns of patients initiated on Vericiguat

    Time frame: At baseline

  3. Description of the use of medications of interest (yes/no) before/after initiation of Vericiguat

    Includes description of prescribed amount of medications of interest in respective observation periods

    Time frame: Up to 12 months

  4. Descriptive measurement of titration patterns

    Includes starting dose, up-titration / down-titration (yes/no), time until target dose

    Time frame: Up to 12 months

  5. Descriptive measurement of treatment discontinuation

    Includes descriptive analysis of number of patients who have discontinued treatment, time points of discontinuation, reasons for discontinuation (Symptomatic hypotension, syncope)

    Time frame: Up to 12 months

Secondary outcomes

  1. Number of patients with hospitalizations due to heart failure after Vericiguat initiation

    Time frame: Up to 12 months

  2. Cardiovascular mortality rate

    Time frame: Up to 12 months

  3. Composite of heart failure hospitalization and cardiovascular mortality

    Time frame: Up to 12 months

  4. Number of patients with symptomatic hypotension or syncope after Vericiguat initiation

    Time frame: Up to 12 months

07

Study locations

1 site
  • Many locations
    Many Locations, India
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2025 to primary completion in Sep 2026, 12 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jun 2026 → Sep 2026 and completion Jun 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2024
First posted
Oct 9, 2024
StartActual
Sep 8, 2025
Primary completionActual
Sep 30, 2026was Jun 2026
CompletionActual
Sep 30, 2026was Jun 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 28, 2026
Sites
1 site added, 1 site removed
Show site
  • Many locations · Many Locations, India
Show 1 removed
  • Many locations · Multiple Locations, India
Oct 28, 2026
Primary completion
Jun 30, 2026→Sep 30, 2026 (actual)
Oct 28, 2026
Study completion
Jun 30, 2026→Sep 30, 2026 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Many locations · Many Locations, India
    Show 1 removed
    • Many locations · Multiple Locations, India
    Primary completion Jun 30, 2026→Sep 30, 2026 (now actual)
    Study completion Jun 30, 2026→Sep 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06632483
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Sep 8, 2025
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Oct 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion